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Abstract
PLE is an important cause of morbidity and mortality in patients who have undergone 
Fontan palliation. While multiple PLE therapies have been reported, none has proved 
consistently effective. Patients who do not respond to “standard” PLE therapies face 
poor long- term outcomes. We report here a significant response to dopamine infusion 
in three patients with chronic, refractory PLE. We hypothesize that this response may 
be at least partially due to a dopamine effect on lymphatic receptors rather than to an 
augmentation of cardiac output.
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1  | INTRODUCTION
PLE is a relatively uncommon but potentially life- threatening compli-
cation of Fontan- palliated single ventricle congenital heart disease. 
PLE is characterized by protein loss through the intestinal lumen with 
a cascade of downstream effects.1 It has been reported in 1%- 13% 
of Fontan patients,2,3 although the potential for asymptomatic dis-
ease coupled with the lack of routine screening makes the true prev-
alence unknown. Mortality of up to 50% has been reported within 
5 years of the diagnosis,2,4 and although survival has likely improved 
in the current era,5 PLE- associated morbidity remains significant with 
 altered calcium metabolism, growth failure, frequent hospitalizations, 
and  increased infection risk related to immune dysfunction common 
among PLE patients.6 Although multiple therapies have been used 
with apparent success in select patients, no therapy short of heart 
transplant has proven to consistently alleviate PLE symptoms. Here, 
we report a significant response to dopamine infusion in three patients 
with chronic, severe PLE unresponsive to standard therapies and dis-
cuss potential physiologic mechanisms for this observed response.
2  | CASE REPORT
Patient 1 was a 19- year- old man with an unbalanced (right dominant) 
atrioventricular septal defect status-post  fenestrated lateral tunnel 
Fontan at 1 ½ years of age. Despite good Fontan hemodynamics, at 
age 9 he developed symptomatic PLE, with hypoalbuminemia and 
elevated fecal α- 1 antitrypsin. He was treated with therapy includ-
ing budesonide, sildenafil, spironolactone, and octreotide and for 
many years required one to two annual admissions for albumin infu-
sion. At age 17, his symptoms worsened dramatically with marked 
fluid overload and persistent hypoalbuminemia. Cardiac catheteri-
zation revealed a Fontan pressure of 13 mm Hg, right ventricular 
end- diastolic pressure of 8 mm Hg, a cardiac index of 3.9 L/min/m2, 
systemic vascular resistance of 12.5 mm Hg/L/min, and pulmonary 
vascular resistance of 1.5 Wood units×m2. His echocardiogram dem-
onstrated mildly depressed right ventricular systolic function and mild 
tricuspid regurgitation. Over the next 2 years, he required 17 admis-
sions for albumin replacement. He developed acute kidney injury dur-
ing one hospitalization, and milrinone was initiated. This resulted in 
acute hypotension, and the milrinone was stopped and replaced with 
dopamine. On dopamine, his kidney injury improved, and his albumin 
level was noted to rapidly stabilize. Of note, there was no apparent 
change in resting heart rate on dopamine, with documented heart 
rates ranging between 80 and 120 bpm before and after dopamine 
was initiated. The patient was discharged home on dopamine and 
required only one admission for PLE (1 month after starting dopa-
mine) over the subsequent 19 months prior to heart transplantation.
Patient 2 was a 21- year- old man with hypoplastic left heart syn-
drome status post- fenestrated lateral tunnel Fontan at 2 years of age. 
He was diagnosed with PLE at age 13, with hypoalbuminemia and 
elevated fecal α- 1 antitrypsin. He was treated with oral budesonide, Abbreviations: bpm, beats per minute; PLE, protein-losing enteropathy.
2 of 3  |     FRIEDLAND- LITTLE ET AL.
sildenafil, heparin, and octreotide and required one to three admis-
sions for albumin replacement per year over the next several years. 
At age 18, his symptoms worsened significantly, with marked fluid 
overload and refractory hypoalbuminemia requiring ongoing outpa-
tient albumin infusions three to four times per week. Cardiac cathe-
terization revealed a mean Fontan pressure of 12 mm Hg, pulmonary 
capillary wedge pressure of 7 mm Hg, a cardiac index of 3.2 L/min/m2, 
a systemic vascular resistance of 20 mm Hg/L/min, and a pulmo-
nary vascular resistance of 1.8 Wood units×m2. His echocardiogram 
revealed normal right ventricular systolic function and mild tricuspid 
regurgitation. Right ventricular systolic function was also normal as 
assessed by cardiac MRI, with an ejection fraction of 55%. Dopamine 
was initiated at 5 μg/kg/min and continued in an outpatient setting. 
Heart rate did not change on dopamine, ranging between 70 and 
110 bpm pre- dopamine and between 60 and 100 bpm on dopamine. 
Within 2 months of dopamine initiation, he had progressively weaned 
to weekly albumin infusions. At the time of transplant, he had weaned 
further and maintained a serum albumin greater than 3.5 mg/dL for 
9 days without supplementation for the first time in more than 3 years.
Patient 3 was a 15- year- old female with hypoplastic left heart syn-
drome status post- lateral tunnel fenestrated Fontan at 23 months of 
age. She was diagnosed with PLE at age 5 and initially responded to 
diuretic therapy and later oral budesonide, but starting at age 12 she 
required increasingly frequent admissions for fluid overload and albu-
min supplementation. She persistently had serum albumin levels be-
tween 2 and 2.5 mg/dL as well as chronic ascites, and she was treated 
with albumin infusions 2- 4 times per month as symptoms dictated. 
Cardiac catheterization revealed a Fontan pressure of 17 mm Hg, a 
right ventricle end- diastolic pressure of 13 mm Hg, a cardiac index of 
2.9 L/min/m2, systemic vascular resistance of 18 mm Hg/L/min, and a 
pulmonary vascular resistance of 0.8 Wood units×m2. Echocardiogram 
demonstrated normal right ventricular systolic function and mild- 
moderate tricuspid insufficiency. Dopamine at 5 μg/kg/min was ini-
tiated at transplant listing. As with the other patients, there was no 
significant change in heart rate, which ranged between 60 and 90 bpm 
before and after dopamine was started. Within 2 weeks, serum albu-
min levels increased and remained >3 mg/dL without supplementation 
and her ascites resolved. After approximately 3 months, the patient 
and family elected not to pursue heart transplantation, so dopamine 
was weaned off. Within 2 weeks of stopping dopamine, her serum al-
bumin level fell to 2 mg/dL with an accompanying 2 kg weight gain 
and return of significant ascites.
3  | DISCUSSION
In this report, we describe three patients with chronic, severe, and 
previously refractory PLE who each demonstrated rapid improve-
ment in PLE symptoms and serum albumin levels after the initiation 
of continuous dopamine. In seeking to explain this response, the ini-
tial assumption may be that dopamine’s inotropic effects improved 
systemic ventricular systolic function and thereby augmented cardiac 
output. Although the pathophysiology of PLE remains unclear, there is 
a body of evidence suggesting that interventions which improve car-
diac output can in some cases improve PLE symptoms.1 The patients 
in our series, however, had normal or only mildly depressed systemic 
ventricular systolic function as assessed by echocardiogram. While 
echocardiogram is an imperfect tool to assess systolic function in a 
systemic right ventricle, all patients had normal resting cardiac out-
put measured in the catheterization laboratory, and the one patient 
for whom MRI data were available had normal systolic function as 
assessed by this modality as well. The degree of improvement in PLE 
symptoms in the patients in this series seems disproportionate to a 
potential augmentation of systolic function assessed as normal or only 
mildly depressed by the modalities available.
There are other potential effects of dopamine in addition to im-
proved contractile function. Dopamine also has chronotropic effects, 
and there is evidence that atrial pacing can improve PLE symptoms 
in patients with sinus node dysfunction.7 None of the patients had 
significant resting chronotropic incompetence, however, and no 
changes in heart rate were documented after dopamine was initiated. 
Another hypothesis is that dopamine increased mesenteric blood 
flow by decreasing mesenteric vascular resistance. There is evidence 
that mesenteric vascular resistance is abnormally elevated in Fontan 
patients with PLE,8,9 and decreased mesenteric perfusion may play 
a role in PLE pathophysiology. Dopamine, particularly at low doses, 
does decrease mesenteric vascular resistance, and an augmentation 
of mesenteric blood flow may have contributed to the therapeutic 
response seen.
Myocardial function and cardiac output of the patients in this se-
ries were only assessed at rest, and it is well documented that Fontan 
patients have reduced exercise capacity and limited ability to augment 
their cardiac output with exertion.10,11 While much of this limitation 
is thought to be secondary to an inability to effectively increase pre-
load in the setting of increased metabolic demands, the inotropic and 
chronotropic effects of dopamine may have improved the ability of 
the patients described here to increase their cardiac output with exer-
cise, and this may also have contributed to some improvement in PLE 
symptoms.
One intriguing alternative hypothesis to explain the improvement 
seen in these patients is that dopamine served to augment lymphatic 
circulation. Recent data suggest dysregulation of lymphatic circulation 
can contribute to the development of PLE in Fontan patients, and me-
chanical blockage of lymphatic drainage can be identified in significant 
numbers of Fontan patients with PLE.12 Surgical decompression of the 
thoracic duct has been shown to relieve symptoms in two Fontan pa-
tients with otherwise refractory PLE.13 Further evidence supporting a 
link between disrupted lymph circulation and PLE in Fontan patients is 
the observation that Fontan patients with PLE display immune abnor-
malities which are also found in patients with PLE secondary to intesti-
nal lymphangiectasia, but not in patients with PLE related to ulcerative 
colitis or celiac disease.14
Normal lymphatic circulation relies on a series of lymph pumps 
and one- way valves to transport lymph fluid from the periphery to 
the thoracic and lymphatic ducts and then into the central venous 
system. This system is in effect a parallel circulatory system, with the 
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intrinsic lymph pumps functioning as a cardiac equivalent, providing 
contractile force for forward lymph flow.15 Like the cardiovascular 
system, the lymphatic system is subject to complex neurohormonal 
regulation that influences both pump contractility and lymph vessel 
compliance. Interestingly, lymph vessels and lymph pumps display 
a relationship to lymphatic pressure and vessel wall stretch that is 
analogous to the Frank- Starling relationship between preload and 
contractility. Increased lymph pressure/stretch (ie, preload) increases 
lymph pump contractile strength up to a point, but beyond that point 
increased pressure/stretch results in decreased contractile strength.15 
The threshold at which this shift occurs varies depending on species 
and physical tissue characteristics, but generally is low. One may 
speculate that the persistently elevated systemic venous pressures 
of Fontan patients may push the “lymphatic Starling curve” too far in 
some patients and lead to decreased contractile strength of the intrin-
sic lymph pumps.
In another analogy to the cardiovascular system, the contrac-
tility of lymphatic vessels can be augmented by inotropic agents, 
including dopamine.15,16 Dopamine has been shown to cause preno-
dal lymphatic constriction in canine models, an effect mediated by 
α- adrenergic receptors.17 While the effect of dopamine on human 
lymphatic contractility is not known, there is evidence that the human 
thoracic duct has significant adrenergic innervation.18 Although the 
potential effect of dopamine on the lymphatic circulation of patients 
in this series remains speculative, presumed dysfunctional lymphatic 
circulation in Fontan patients with PLE may serve as a target for phar-
macologic intervention and direct new potential avenues for research.
In conclusion, chronic dopamine infusion may be an effective ther-
apy for refractory PLE in some patients. The mechanism by which do-
pamine may improve PLE is unclear, and further study is needed to 
confirm the potential therapeutic benefit of dopamine as an additional 
treatment modality for PLE as well as to clarify its mechanism of action 
in this setting.
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